These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 8698440)

  • 21. Does the combination of cilazapril and propranolol lower blood pressure at rest and during exercise more pronouncedly than either of the two components given alone?
    Erb KA; Breithaupt K; Kleinbloesem CH; Wolf GK; Belz GG
    Clin Physiol Biochem; 1990; 8 Suppl 2():35-45. PubMed ID: 2151315
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effects of antihypertensive treatment on vascular remodeling in essential hypertensive patients.
    Schiffrin EL; Deng LY; Larochelle P
    J Cardiovasc Pharmacol; 1994; 24 Suppl 3():S51-6. PubMed ID: 7700067
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Antihypertensive, enzymatic, and hormonal activity of cilazapril, a new angiotensin-converting enzyme inhibitor in patients with mild to moderate essential hypertension.
    Sánchez RA; Traballi CA; Barclay CA; Gilbert HB; Muscará M; Giannone C; Moledo LI
    J Cardiovasc Pharmacol; 1988 Feb; 11(2):230-4. PubMed ID: 2452319
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Long-term changes in the response of conductance and resistance coronary vessels to endothelium-dependent and independent vasodilators. A double-blind placebo-controlled study of the effect of a 6-month treatment with cilazapril.
    Di Mario C; Strikwerda S; Gil R; Azar A; Rames A; Serruys PW
    Ital Heart J; 2000 Oct; 1(10):674-83. PubMed ID: 11061364
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Is endothelial function of the radial artery altered in human essential hypertension?
    Schmieder RE; Weihprecht H; Schobel H; John S; Weidinger G; Gatzka C; Veelken R
    Am J Hypertens; 1997 Mar; 10(3):323-31. PubMed ID: 9056690
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effects of ACE inhibition with cilazapril on splanchnic and systemic haemodynamics in man.
    Gasic S; Heinz G; Kleinbloesem C; Korn A
    Br J Clin Pharmacol; 1989; 27 Suppl 2(Suppl 2):225S-234S. PubMed ID: 2548552
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effects of cilazapril on cardiac structure and function in hypertension.
    Moisejev VS; Ivleva AY; Gurochkin AB; Kobalava ZD
    J Cardiovasc Pharmacol; 1994; 24 Suppl 3():S70-2. PubMed ID: 7700070
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Bradykinin type 2 receptor BE1 genotype influences bradykinin-dependent vasodilation during angiotensin-converting enzyme inhibition.
    Van Guilder GP; Pretorius M; Luther JM; Byrd JB; Hill K; Gainer JV; Brown NJ
    Hypertension; 2008 Feb; 51(2):454-9. PubMed ID: 18180402
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Nebivolol reverses endothelial dysfunction in essential hypertension: a randomized, double-blind, crossover study.
    Tzemos N; Lim PO; MacDonald TM
    Circulation; 2001 Jul; 104(5):511-4. PubMed ID: 11479245
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effects of angiotensin converting enzyme inhibitors and of hydralazine on endothelial function in hypertensive rats.
    Clozel M; Kuhn H; Hefti F
    Hypertension; 1990 Nov; 16(5):532-40. PubMed ID: 2146221
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effects of angiotensin-converting enzyme inhibition versus beta-adrenergic blockade on aortic stiffness in essential hypertension.
    Savolainen A; Keto P; Poutanen VP; Hekali P; Standertskjöld-Nordenstam CG; Rames A; Kupari M
    J Cardiovasc Pharmacol; 1996 Jan; 27(1):99-104. PubMed ID: 8656666
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Defective L-arginine-nitric oxide pathway in offspring of essential hypertensive patients.
    Taddei S; Virdis A; Mattei P; Ghiadoni L; Sudano I; Salvetti A
    Circulation; 1996 Sep; 94(6):1298-303. PubMed ID: 8822983
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Preserved endothelium-dependent vasodilatation in patients with essential hypertension.
    Cockcroft JR; Chowienczyk PJ; Benjamin N; Ritter JM
    N Engl J Med; 1994 Apr; 330(15):1036-40. PubMed ID: 8127330
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effects of cerivastatin on forearm vascular responses, blood pressure responsiveness and ambulatory blood pressure in type 2 diabetic men.
    Tran D; Lowy A; Howes JB; Howes LG
    Diabetes Obes Metab; 2005 May; 7(3):273-81. PubMed ID: 15811145
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Indirect evidence for release of endothelium-derived relaxing factor in human forearm circulation in vivo. Blunted response in essential hypertension.
    Linder L; Kiowski W; Bühler FR; Lüscher TF
    Circulation; 1990 Jun; 81(6):1762-7. PubMed ID: 2344673
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effect of increased availability of endothelium-derived nitric oxide precursor on endothelium-dependent vascular relaxation in normal subjects and in patients with essential hypertension.
    Panza JA; Casino PR; Badar DM; Quyyumi AA
    Circulation; 1993 May; 87(5):1475-81. PubMed ID: 8491002
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The effects of the long-acting angiotensin-converting enzyme inhibitor cilazapril on casual, exercise, and ambulatory blood pressure.
    White WB; McCabe EJ; Hager WD; Schulman P
    Clin Pharmacol Ther; 1988 Aug; 44(2):173-8. PubMed ID: 2969315
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Angiotensin II inhibits the forearm vascular response to increased arterial pressure in humans.
    Goldsmith SR; Hasking GJ
    J Am Coll Cardiol; 1995 Jan; 25(1):246-50. PubMed ID: 7798510
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Dose-finding study of cilazapril (Inhibace) in patients with uncomplicated essential hypertension.
    Mroczek WJ; Klein J; Burris JF
    Clin Exp Hypertens A; 1991; 13(8):1415-32. PubMed ID: 1836986
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Comparative and double-blind study of the efficacy and safety of cilazapril compared to nifedipine retard in the treatment of mild and moderate arterial hypertension].
    Velasco-Cornejo IF; Mion Júnior D; Martin LC; Tinucci T; Sampaio M; Pascoal IJ; Athanázio-Heliodoro RC; Marcondes M; Franco RJ
    Arq Bras Cardiol; 1994 Mar; 62(3):159-64. PubMed ID: 7980076
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.